NCT06413914 Evaluation of Cognitive Behavioral Therapy for Long-term Pain in Rheumatic Disease, Including Validation of AE-FS
| NCT ID | NCT06413914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Diakonhjemmet Hospital |
| Condition | Rheumatic Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-16 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-01-16 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Catastrophic thinking is a risk factor for a poor prognosis for pain in general and rheumatic disease in particular, which for many contributes to a behavioral pattern characterized by avoidance. Other people with long-term pain, on the other hand, have a pattern where they suppress thoughts and feelings of fear associated with pain, and push themselves to carry out activities. An inappropriate form of endurance can help maintain and intensify pain. The AE-FS is a short version of the Avoidance-Endurance Questionnaire with different subscales for maintaining activity despite pain. AE-FS can be of great clinical utility. The study of patients with rheumatic disease and long-term pain will validate a Norwegian version of the AE-FS as well as examine how the AE-FS seen in connection with other relevant questionnaires, including the Pain Catastrophizing Scale , reflects mechanisms for change in cognitive behavioral therapy for long-term pain. The effect of the intervention is evaluated with questionnaires at baseline/start of treatment, end of treatment, two months after end of treatment and after six months.
Eligibility Criteria
Inclusion Criteria: * A rheumatic disorder and a long term pain condition * Written consent Exclusion Criteria: * Participation in another therapy during the study periode
Contact & Investigator
Erik Soegaard, PhD
STUDY CHAIR
Diakonhjemmet Hospital
Frequently Asked Questions
Who can join the NCT06413914 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06413914 currently recruiting?
Yes, NCT06413914 is actively recruiting participants. Contact the research team at kare.osnes@diakonsyk.no for enrollment information.
Where is the NCT06413914 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT06413914 clinical trial?
NCT06413914 is sponsored by Diakonhjemmet Hospital. The principal investigator is Erik Soegaard, PhD at Diakonhjemmet Hospital. The trial plans to enroll 200 participants.